Some cholesterol absorption inhibitors reduce elevated hepatic markers enzymes and thereby lowered NAFLD occurrence by inhibiting LXRα-SREBP-1c pathway. This evidence concerns the gene NR1H3 and metabolic dysfunction-associated steatotic liver disease.